Medicare spells out what the new Alzheimer’s drug registries will collect

As part of ef­forts to im­prove ac­cess to drugs that may slow the pro­gres­sion of Alzheimer’s dis­ease, Medicare re­it­er­at­ed that it will cov­er new an­ti-amy­loid drugs with full or tra­di­tion­al ap­proval, and now it’s spelling out how it wants re­al-world da­ta to be col­lect­ed to study the use­ful­ness of these drugs.

Ei­sai and Bio­gen’s Leqem­bi (lecanemab) is like­ly to be the first of the amy­loid-tar­get­ed mon­o­clon­al an­ti­bod­ies to win full ap­proval, with a PDU­FA date of Ju­ly 6. That full ap­proval will set off al­most im­me­di­ate cov­er­age from CMS, in­creas­ing ac­cess for the first time.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN